Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
10 pending office actions • 4 art units • 5 examiners • 0 of 10 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Encapsys LLC has 10 pending office actions in Biotechnology & Pharmaceuticals, involving 5 examiners across 4 art units. PHAN, DOAN THI-THUC is the busiest examiner, with 6 pending actions.
A substantial share of the active docket is concentrated with the busiest examiner, making examiner-specific prosecution planning especially relevant. At the same time, the presence of multiple art units means that a single response template may not address every matter. Counsel should separate common technical themes from issues tied to individual examination assignments.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| Double-patenting + other | 5 (50%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PHAN, DOAN THI-THUC | 6 | 42.8% | +47.6% |
| OGDEN JR, NECHOLUS | 1 | 69.7% | +23.7% |
| DELCOTTO, GREGORY R | 1 | 54.1% | +75.7% |
| LE, HOA T | 1 | 72.7% | +11.9% |
| GOTFREDSON, GAREN | 1 | 39.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17529554 | Poly Acrylate and Poly(Beta-Amino Ester) Capsules with Enhanced Degradability | PHAN, DOAN THI-THUC | 17d overdue |
| 18475472 | Delivery Particles Based On Amine-Thiol-Ene Conjugates and Derivatives | PHAN, DOAN THI-THUC | 16d overdue |
| 18874388 | TREATMENT COMPOSITION WITH PERFUME-CONTAINING DELIVERY PARTICLES | OGDEN JR, NECHOLUS | — |
| 18252822 | BIODEGRADABLE DELIVERY PARTICLES | PHAN, DOAN THI-THUC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554018 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | PHAN, DOAN THI-THUC | 43d overdue |
| 18462537 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | PHAN, DOAN THI-THUC | 43d overdue |
| 17529554 | Poly Acrylate and Poly(Beta-Amino Ester) Capsules with Enhanced Degradability | PHAN, DOAN THI-THUC | 17d overdue |
| 18475472 | Delivery Particles Based On Amine-Thiol-Ene Conjugates and Derivatives | PHAN, DOAN THI-THUC | 16d overdue |
| 18754389 | COMPOSITIONS OF PLANT-BASED FLOUR DELIVERY PARTICLES | LE, HOA T | 8d |
| 18874388 | TREATMENT COMPOSITION WITH PERFUME-CONTAINING DELIVERY PARTICLES | OGDEN JR, NECHOLUS | — |
| 18872341 | TREATMENT COMPOSITION WITH CHITOSAN-BASED DELIVERY PARTICLES | DELCOTTO, GREGORY R | — |
| 18771223 | MULTIFUNCTIONAL (METH)ACRYLATE POLYSACCHARIDE MICROCAPSULES | GOTFREDSON, GAREN | — |
| Art Unit | Apps |
|---|---|
| 1613 | 6 |
| 1761 | 2 |
| 1788 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874388 | TREATMENT COMPOSITION WITH PERFUME-CONTAINING DELIVERY PARTICLES | OGDEN JR, NECHOLUS | 1761 | §102§112 | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18872341 | TREATMENT COMPOSITION WITH CHITOSAN-BASED DELIVERY PARTICLES | DELCOTTO, GREGORY R | 1761 | §102§112DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18754389 | COMPOSITIONS OF PLANT-BASED FLOUR DELIVERY PARTICLES | LE, HOA T | 1788 | §103 | Non-Final OA | 8d | Pending | Jul 18, 2024 |
| 18771223 | MULTIFUNCTIONAL (METH)ACRYLATE POLYSACCHARIDE MICROCAPSULES | GOTFREDSON, GAREN | 1619 | §103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18554018 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | PHAN, DOAN THI-THUC | 1613 | §103DP | Final Rejection | 43d overdue | Pending | Oct 05, 2023 |
| 18475472 | Delivery Particles Based On Amine-Thiol-Ene Conjugates and Derivatives | PHAN, DOAN THI-THUC | 1613 | §103§112 | Final Rejection | 16d overdue | Pending | Sep 27, 2023 |
| 18462537 | DELIVERY PARTICLES WITH HIGH CORE:WALL RATIOS | PHAN, DOAN THI-THUC | 1613 | §102§103§112DP | Final Rejection | 43d overdue | Pending | Sep 07, 2023 |
| 18252835 | BIODEGRADABLE DELIVERY PARTICLES | PHAN, DOAN THI-THUC | 1613 | §103§112DP | Non-Final OA | — | Pending | May 12, 2023 |
| 18252822 | BIODEGRADABLE DELIVERY PARTICLES | PHAN, DOAN THI-THUC | 1613 | §103§112 | Non-Final OA | — | Pending | May 12, 2023 |
| 17529554 | Poly Acrylate and Poly(Beta-Amino Ester) Capsules with Enhanced Degradability | PHAN, DOAN THI-THUC | 1613 | §103§112 | Final Rejection | 17d overdue | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEncapsys LLC has 10 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Doan Thi-Thuc Phan has the most, with 6 of Encapsys LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
